AU2006299818A1 - Development of prodrugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety using in vitro/in silico predictions - Google Patents

Development of prodrugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety using in vitro/in silico predictions Download PDF

Info

Publication number
AU2006299818A1
AU2006299818A1 AU2006299818A AU2006299818A AU2006299818A1 AU 2006299818 A1 AU2006299818 A1 AU 2006299818A1 AU 2006299818 A AU2006299818 A AU 2006299818A AU 2006299818 A AU2006299818 A AU 2006299818A AU 2006299818 A1 AU2006299818 A1 AU 2006299818A1
Authority
AU
Australia
Prior art keywords
unsubstituted
substituted
formula
nitric oxide
chain alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006299818A
Other languages
English (en)
Inventor
Christopher Mark Diaper
Yi-Chan James Lin
Douglas Thacher Ridgway
Hugh A. Semple
Brian Duff Sloley
Yun Kau Tam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOVOKIN BIOTECH Inc
Original Assignee
NOVOKIN BIOTECH Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NOVOKIN BIOTECH Inc filed Critical NOVOKIN BIOTECH Inc
Publication of AU2006299818A1 publication Critical patent/AU2006299818A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2006299818A 2005-10-13 2006-10-13 Development of prodrugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety using in vitro/in silico predictions Abandoned AU2006299818A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US72653005P 2005-10-13 2005-10-13
US60/726,530 2005-10-13
US73012005P 2005-10-21 2005-10-21
US60/730,120 2005-10-21
US75644606P 2006-01-05 2006-01-05
US60/756,446 2006-01-05
US81223006P 2006-06-09 2006-06-09
US60/812,230 2006-06-09
PCT/US2006/040382 WO2007044963A2 (fr) 2005-10-13 2006-10-13 Développement de promédicaments possédant une entité 1,2-diolate de diazén-1-ium donneuse d'oxyde nitrique en utilisant des prédictions in vitro/in silico

Publications (1)

Publication Number Publication Date
AU2006299818A1 true AU2006299818A1 (en) 2007-04-19

Family

ID=37943584

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006299818A Abandoned AU2006299818A1 (en) 2005-10-13 2006-10-13 Development of prodrugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety using in vitro/in silico predictions

Country Status (5)

Country Link
EP (1) EP1934872A2 (fr)
JP (1) JP2009515824A (fr)
AU (1) AU2006299818A1 (fr)
CA (1) CA2622150A1 (fr)
WO (1) WO2007044963A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102043892B (zh) * 2009-10-23 2014-04-02 上海开拓者医药发展有限公司 用于原料药胃肠道吸收预测的bspk模型的建模和使用方法
US8633177B2 (en) 2010-03-19 2014-01-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxyl (HNO) releasing compounds and uses thereof in treating diseases
US9604949B2 (en) * 2014-10-15 2017-03-28 Novartis Ag Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension
CN115512788B (zh) * 2022-09-16 2023-08-08 山东大学 预测SGLTi人体暴露量及靶蛋白抑制率的方法及系统

Also Published As

Publication number Publication date
JP2009515824A (ja) 2009-04-16
CA2622150A1 (fr) 2007-04-19
WO2007044963A3 (fr) 2009-04-30
WO2007044963A2 (fr) 2007-04-19
WO2007044963A8 (fr) 2007-06-14
EP1934872A2 (fr) 2008-06-25

Similar Documents

Publication Publication Date Title
US20080288176A1 (en) Development of Prodrugs Possessing a Nitric Oxide Donor Diazen-1-Ium-1,2-Diolate Noiety Using in Vitro/in Silico Predictions
Ji et al. Click and release: bioorthogonal approaches to “on-demand” activation of prodrugs
Li et al. Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative
Gedawy et al. Design, synthesis and biological evaluation of novel pyrazole sulfonamide derivatives as dual COX-2/5-LOX inhibitors
Ferrario Angiotensin-converting enzyme 2 and angiotensin-(1-7) an evolving story in cardiovascular regulation
Elliott et al. Sirtuins: novel targets for metabolic disease
Velázquez et al. Second-generation aspirin and indomethacin prodrugs possessing an O 2-(Acetoxymethyl)-1-(2-carboxypyrrolidin-1-yl) diazenium-1, 2-diolate nitric oxide donor moiety: design, synthesis, biological evaluation, and nitric oxide release studies
Marathe et al. The use of radiolabeled compounds for ADME studies in discovery and exploratory development
Paumi et al. Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Δ12, 14prostaglandin J2 in MCF7 breast cancer cells
Sidhapuriwala et al. Effect of S-diclofenac, a novel hydrogen sulfide releasing derivative, on carrageenan-induced hindpaw oedema formation in the rat
Zhao et al. Cyclic sulfenyl thiocarbamates release carbonyl sulfide and hydrogen sulfide independently in thiol-promoted pathways
More et al. Design, synthesis and biological evaluation of glutathione peptidomimetics as components of anti-Parkinson prodrugs
Mondal et al. Chemical biology of protein citrullination by the protein A arginine deiminases
AU2006299818A1 (en) Development of prodrugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety using in vitro/in silico predictions
Kaur et al. Synthesis and biological investigations of nitric oxide releasing nateglinide and meglitinide type II antidiabetic prodrugs: In-vivo antihyperglycemic activities and blood pressure lowering studies
Martelli et al. The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endothelial dysfunction
Sharma et al. Synthesis and evaluation of fluorobenzoylated di-and tripeptides as inhibitors of cyclooxygenase-2 (COX-2)
Kim et al. Hit-to-lead optimization of phenylsulfonyl hydrazides for a potent suppressor of PGE2 production: Synthesis, biological activity, and molecular docking study
Passioura The road ahead for the development of macrocyclic peptide ligands
Moss et al. Structure-based design of reactive nucleosides for site-specific modification of the A2A adenosine receptor
Stensrud et al. Competing pathways in the photo-Favorskii rearrangement and release of esters: studies on fluorinated p-hydroxyphenacyl-caged GABA and glutamate phototriggers
Ohlan et al. Mutual prodrugs–A swot analysis
Ganai et al. Delineating binding potential, stability of Sulforaphane‐N‐acetyl‐cysteine in the active site of histone deacetylase 2 and testing its cytotoxicity against distinct cancer lines through stringent molecular dynamics, DFT and cell‐based assays
US20100310540A1 (en) Methods of screening for compounds that modulate tafia activity, compounds, and methods of using the compounds
McMorris et al. Preparation and biological activity of amino acid and peptide conjugates of antitumor hydroxymethylacylfulvene

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period